211 related articles for article (PubMed ID: 17321998)
1. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
Okabe S; Tauchi T; Ishii Y; Akahane D; Nunoda K; Honda S; Takaku T; Ohyashiki K
Int J Hematol; 2007 Feb; 85(2):173-4. PubMed ID: 17321998
[No Abstract] [Full Text] [Related]
2. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
[TBL] [Abstract][Full Text] [Related]
3. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
[TBL] [Abstract][Full Text] [Related]
4. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
Marin D; Goldman JM; Olavarria E; Apperley JF
Blood; 2003 Oct; 102(7):2702-3; author reply 2703-4. PubMed ID: 14504074
[No Abstract] [Full Text] [Related]
5. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
Petzer AL; Wolf D; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Oucheva R; Ulmer H; Kwakkelstein M; Rancati F; Gastl G
Haematologica; 2010 Jun; 95(6):908-13. PubMed ID: 20145273
[TBL] [Abstract][Full Text] [Related]
6. New drug targets genetic malfunction in chronic myeloid leukemia.
Am J Health Syst Pharm; 2001 Jul; 58(14):1282. PubMed ID: 11471471
[No Abstract] [Full Text] [Related]
7. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
Sohn SK; Moon JH; Cho YY; Chae YS; Kim JG; Lee KS; Hong SP; Kim SO
Leuk Lymphoma; 2007 Aug; 48(8):1659-61. PubMed ID: 17701605
[No Abstract] [Full Text] [Related]
8. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Yujiri T; Sato Y; Tanizawa Y
Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia: where do we go now?
Cortés JE
Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
[No Abstract] [Full Text] [Related]
10. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
Rosário Cavalheiro Rde C; Vicari P; Maria Morselli F; Ommati LV; Frazão Rosa Fde O; Rodrigues Oliveira JS
Am J Hematol; 2006 Jan; 81(1):76-7. PubMed ID: 16369975
[No Abstract] [Full Text] [Related]
11. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
Kiguchi T; Tauchi T; Ohyashiki K
Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
[TBL] [Abstract][Full Text] [Related]
12. Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia.
Kobayashi K; Takebayashi C; Miyata S; Narimatsu H; Kami M
Intern Med; 2009; 48(5):369-71. PubMed ID: 19252364
[TBL] [Abstract][Full Text] [Related]
13. Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.
Morán VP; Baute RG; Facundo JC; Ramírez PH; Núñez AA; Martínez EE; Cabrera OM; Padrón CH; Otero AG; Uría JC; Estrada EE; Díaz RM; Virgil AM; Sánchez KL; Cabeza AH
MEDICC Rev; 2011 Jan; 13(1):35-40. PubMed ID: 21273957
[TBL] [Abstract][Full Text] [Related]
14. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
[TBL] [Abstract][Full Text] [Related]
15. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
Poláková KM; Polívková V; Rulcová J; Klamová H; Jurcek T; Dvoráková D; Zácková D; Pospísil Z; Mayer J; Moravcová J
Exp Hematol; 2010 Jan; 38(1):20-6. PubMed ID: 19837125
[TBL] [Abstract][Full Text] [Related]
16. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
Colombat M; Fort MP; Chollet C; Marit G; Roche C; Preudhomme C; Reiffers J; Praloran V; Mahon FX
Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299
[TBL] [Abstract][Full Text] [Related]
17. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
Matsuo E; Miyazaki Y; Tsutsumi C; Inoue Y; Yamasaki R; Hata T; Fukushima T; Tsushima H; Imanishi D; Imaizumi Y; Iwanaga M; Sakai M; Ando K; Sawayama Y; Ogawa D; Kawaguchi Y; Nagai K; Tsukasaki K; Ikeda S; Moriuchi Y; Yoshida S; Honda M; Taguchi J; Onimaru Y; Tsuchiya T; Tawara M; Atogami S; Yamamura M; Soda H; Yoshida Y; Matsuo Y; Nonaka H; Joh T; Takasaki Y; Kawasaki C; Momita S; Jinnai I; Kuriyama K; Tomonaga M
Int J Hematol; 2007 Feb; 85(2):132-9. PubMed ID: 17321991
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Quintas-Cardama A; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Rios MB; Hayes K; Glassman A; Bekele BN; Zhou X; Cortes J
Blood; 2005 Mar; 105(6):2281-6. PubMed ID: 15572595
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
Lazarevic V; Golovleva I; Nygren I; Wahlin A
Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
[No Abstract] [Full Text] [Related]
20. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
Rousselot P; Huguet F; Rea D; Legros L; Cayuela JM; Maarek O; Blanchet O; Marit G; Gluckman E; Reiffers J; Gardembas M; Mahon FX
Blood; 2007 Jan; 109(1):58-60. PubMed ID: 16973963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]